Our Take
Utilization spikes are outpacing price growth, which means the problem isn't just that drugs cost more—it's that far more people are using them, and that's harder to control.
Why it matters
Health insurers and employers planning 2025 budgets need to account for volume-driven spending, not just cost-per-unit inflation. GLP-1 adoption is accelerating faster than policy or pricing models anticipated.
Do this week
Payers: model your 2025 pharmacy spend by GLP-1 utilization rates (not list price alone) before Q1 forecasting closes so you can adjust reserve margins.
US health spending accelerates to $5.7 trillion in 2025
The Centers for Medicare and Medicaid Services projects total US health spending will reach $5.7 trillion in 2025, according to CMS actuaries cited by Healthcare Dive. The acceleration is driven primarily by utilization growth, not cost-per-service inflation.
Prescription drug spending is the sharpest contributor. GLP-1 medications (semaglutide, tirzepatide, and related compounds) are cited as especially acute drivers. The volume of prescriptions is rising faster than historical trends, outpacing both price growth and overall enrollment expansion.
Utilization, not inflation, is the real budget shock
The standard story in healthcare economics is rising unit costs: drug prices go up, procedure fees climb, insurance premiums follow. This projection reverses the emphasis. CMS data (per Healthcare Dive) suggests that more people are using healthcare services more often, and that behavioral shift is the primary cost driver.
For payers and employers, this distinction matters operationally. Price negotiations and fee schedules address per-unit costs. Utilization trends require different levers: prior authorization tightening, step therapy protocols, or acceptance that demand is simply higher and sustained.
GLP-1 adoption is a concrete case. These drugs are prescribed not just for diabetes management but increasingly for weight loss and cardiovascular prevention. Insurance coverage expansion and direct-to-consumer marketing have broadened the eligible population far beyond endocrinology. The result is spending growth that supply-side cost controls alone cannot arrest.
Lock in your utilization baselines now
If you manage health benefits, pharmacy costs, or actuarial forecasting, treat the 2025 projection as a floor, not a ceiling. GLP-1 utilization continues to accelerate, and CMS's current estimate may already lag real-world adoption rates by mid-year.
Document current prescription patterns by drug class, employer size, and age cohort. Model scenarios where GLP-1 penetration increases by 50%, 100%, or more. Negotiate pharmacy rebates and carve-out terms now, while vendors still have room to move. Once utilization hits inflection, negotiating leverage disappears.